GPs in England are now allowed to prescribe Mounjaro to severely obese people who also suffer from a range of other health ...

Novo Nordisk ends partnership with Hims & Hers over compounded Wegovy, shaking the market. See why I recommend a wait-and-see ...

The report spotlights China’s rapid biopharma advancement, alongside a GLP-1 surge, caution surrounding M&A, and a rise in ...

US pharma major Eli Lilly (NYSE: LLY) spotlighted new safety and efficacy data for its investigational oral GLP-1 therapy ...

Shares in two companies slide as Danish drugmaker accuses US telehealth group of deceptively marketing replica treatments ...

The TSX Composite Index rolled on 155.24 points to move into Monday afternoon at 26,652.81. The Canadian dollar regrouped 0.05 cents to 72.82 cents U.S. Over the weekend, the U.S. had launched strikes ...

The Wegovy maker says the telehealth company didn't stop selling compounded versions of the blockbuster drug after Novo ...

While Eli Lilly brushed off concerns about gastrointestinal side effects for oral weight loss candidate orforglipron, ...

Novo Nordisk's U.S.-listed shares fell more than 5% Monday after the drugmaker revealed the latest results for a new weight-loss treatment.

Novo Nordisk (NVO) and Hims and Hers Health (HIMS) shares are sinking on an ended partnership, with the former also ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...